SEC Tracker
Get the app

Amarin AMRN

Amarin reports Q3 2026 results

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Results for three and nine months ended September 30, 2026 and 2025
  2. Exhibit 99.1 includes the press release

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Amarin files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Rigel Pharmaceuticals RIGL public float $332M, Jun 30, 2025
  2. Northwest Biotherapeutics NWBO public float $340M, Jun 30, 2025
  3. Usana Health Sciences USNA public float $328M, Jun 27, 2025
  4. Emergent BioSolutions EBS public float $343M, Jun 30, 2025
  5. Altimmune ALT public float $327M, Jun 30, 2025